AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01698710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin bound paclitaxel
Description: Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
Study NCT03513445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study NCT03513445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Study NCT00648947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Bisulfate Tablets 75 mg
Description: 75mg, single dose fasting
Study NCT00648947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® Tablets 75 mg
Description: 75mg, single dose fasting
Study NCT01661114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01661114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT01661114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01863030 — intervention group
Intervention type: DEVICE
Intervention: Phasix mesh implant
Study NCT01560767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
Study NCT01560767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peri-articular infiltration
Description: The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
Study NCT01878344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC
Study NCT01878344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT05673317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding at AU Smartphone Application
Description: This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
Study NCT04000815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C Type Natriüretic Peptide
Description: C Type Natriuretic Peptide will be measured with elisa method
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00448019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV over 30 minutes daily for 3 days
Study NCT00448019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2 IV over 30 minutes daily for 3 days
Study NCT00448019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.
Study NCT00448019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
Study NCT00804180 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Injection Anxiety Counseling
Description: This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
Study NCT02514876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foresight ICE System
Description: The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
Study NCT00875030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate sachets
Description: single dose 50 mg (2 X 25 mg) artesunate sachets
Study NCT00875030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsuamoon
Description: single dose 50 mg arsuamoon tablet
Study NCT02898168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WA group
Description: Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
Study NCT02898168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional rehabilitation therapy and gait training without WA.
Study NCT00995241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 800 mg / 24 hours.
Study NCT01700244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implant
Study NCT01425060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive management program
Description: The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
Study NCT01425060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
Study NCT05278325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Description: Two planned phone call between clinical controls
Study NCT02517684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Study NCT02517684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT02517684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive enteral nutrition
Study NCT02517684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Study NCT02517684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Study NCT03197883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Restoring lipid balm
Study NCT03197883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanser
Description: Moisturizing facial cleanser
Study NCT03197883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser
Description: Moisturizing facial cleanser
Study NCT03197883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: SPF (Sun Protection Factor) 50 sunscreen
Study NCT03197883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen
Description: SPF (Sun Protection Factor) 50 sunscreen
Study NCT01240291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dipeptiven
Description: Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
Study NCT01240291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
Study NCT04370639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuFlow sensor
Description: AccuFlow sensor will be worn and survey completed
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT04370639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
Study NCT02882945 — intervention group
Intervention type: OTHER
Intervention: Group A
Description: 150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
Study NCT02882945 — intervention group
Intervention type: OTHER
Intervention: Group B
Description: 200 cases of type 2 DM without complications were enrolled in the study.
Study NCT02882945 — intervention group
Intervention type: OTHER
Intervention: Group C
Description: 120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
Study NCT03217903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myelogram
Description: Bone marrow aspiration after 3 cycles of Azacytidine treatment
Study NCT01751048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
Study NCT01751048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3
Description: LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
Study NCT01751048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPL-SE
Description: Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
Study NCT01751048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SE
Description: Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
Study NCT02255708 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Neuromuscular Facilitation - PNF
Study NCT03325192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid pleurodesis protocol
Description: * The pleural space will be evacuated completely through the newly placed IPC~* 20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis.
Study NCT03325192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * The pleural space will be evacuated completely through the newly placed IPC~* Only placebo (normal saline) will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis.
Study NCT01450189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV prevention messages
Description: A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
Study NCT01450189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI: Information-Motivation-Behavioral Skills Model
Description: The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
Study NCT01450189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: raltegravir (400 mg) administered orally twice daily for 12 weeks
Study NCT01450189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate
Description: emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
Study NCT03799653 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a prospective observational study, and there is no intervention.
Study NCT02157636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0610
Study NCT01921062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
Study NCT03513445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naropin
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study NCT02830438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear wave elastography
Description: Ultrasound technique of the kidneys to assess wave elastography.
Study NCT01230177 — intervention group
Intervention type: DRUG
Intervention: etanercept (genetical recombination)
Description: 10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
Study NCT02194257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-cyclohexane ambroxol oral solution
Study NCT02194257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzyl ambroxol oral solution
Study NCT02194257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol lozenge
Study NCT01659580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 high dose
Description: 225mg bid
Study NCT01659580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 Low dose
Description: 150mg bid
Study NCT01659580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanqi+Bingpian
Description: 225 mg bid
Study NCT01659580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 225mg bid
Study NCT00075478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00075478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00075478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00075478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00075478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00075478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00075478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Given PO
Study NCT01534182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg orally once a day
Study NCT01534182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta - 1a (IFN)
Description: 44 mcg subcutaneously three times a week
Study NCT01534182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate (GA)
Description: 20 mg subcutaneously once a day
Study NCT01479283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered.
Study NCT01479283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered.
Study NCT00770146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mipomersen sodium
Description: 200 mg/mL
Study NCT00770146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
Study NCT02158364 — intervention group
Intervention type: DRUG
Intervention: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Description: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Study NCT01782001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: vitamin A with placebo
Study NCT01782001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A and zinc
Description: combination of vitamin A and zinc supplements
Study NCT01592656 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax. At baseline, after 1 month and after 6 months.
Study NCT01592656 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax. At baseline, after 1 month and after 6 months.
Study NCT01592656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lung compliance measurement
Description: At baseline
Study NCT01592656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lung compliance measurement
Description: At baseline
Study NCT01592656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation (Respironics)
Description: Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 > 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
Study NCT03027284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally
Study NCT03027284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study NCT03027284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT02915874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide